Margaret M. Woo

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Daniel J. DeAngelo, Andrew Spencer, Kapil N. Bhalla et al. · Leukemia · 2013 · 137 citations

Dose-escalation Study, Hematological Malignancy, Oncology +8

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

Dana E. Rathkopf, Bryan Wong, Robert W. Ross et al. · Cancer Chemotherapy and Pharmacology · 2010 · 112 citations

Urology, Oncology, Genitourinary Cancer +4

Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients

Sally Clive, Margaret M. Woo, Thomas Nydam et al. · Cancer Chemotherapy and Pharmacology · 2012 · 56 citations

Oncology, Pancreatic Cancer, Medicine +8

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

Oliver G. Ottmann, Andrew Spencer, H. Miles Prince et al. · Blood · 2008 · 50 citations

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

Seongwook Jeong, Margaret M. Woo, David A. Flockhart et al. · Cancer Chemotherapy and Pharmacology · 2009 · 45 citations · Full text

Major Oxidative Metabolite, Medicinal Chemistry, Pharmacological Study +8